

**Table 1. Detection of antiviral drug-resistant viruses in Japan during the 2022/2023 influenza season**

as of April 7, 2023

	A(H1N1)pdm09						A(H3N2)						B				
	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir
<b>Resistant (%)</b>	0	0	0	0	0	6 (100%)	0	0	0	0	0	81 (100%)	0	0	0	0	0
<b>Number of viruses tested</b>	4	9	9	6	6	6	99	76	76	76	76	81	1	7	7	7	7
<b>Number of viruses reported</b>	31						1,486						25				

Baloxavir was examined by focus reduction assay and/or PA sequencing.

NA inhibitors were examined by fluorescence-based NA-Fluor assay, chemiluminescence-based NA-XTD assay, real time RT-PCR allelic discrimination and/or NA sequencing.

Amantadine was examined by M2 sequencing.